Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119676 | 0.91 | LMNA (0.46) | LMNATHRBHPGDL3MBTL1ALDH1A1 | |
| SCHEMBL427205 | 0.83 | KDM4E (0.53) | LMNATHRBHPGDL3MBTL1FAAH | |
| SCHEMBL5651399 | 0.81 | ALDH1A1 (0.53) | HPGDALDH1A1FAAHMGLLTSHR | |
| SCHEMBL9906756 | 0.77 | L3MBTL1 (0.57) | LMNATHRBHPGDL3MBTL1ALDH1A1 | |
| SCHEMBL9471589 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPSR1FAAHMGLLPOLB | |
| SCHEMBL27452187 | 0.73 | CYP19A1 (0.49) | L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL5648204 | 0.73 | CYP1A2 (0.51) | LMNAHPGDKMT2ACYP3A4 | |
| SCHEMBL1424751 | 0.73 | CYP19A1 (0.47) | L3MBTL1FAAHMGLLTSHRCYP24A1 | |
| SCHEMBL1260765 | 0.71 | FAAH (0.52) | ALDH1A1FAAHMGLLPOLBCYP24A1 | |
| SCHEMBL24937727 | 0.71 | NPSR1 (0.50) | LMNATHRBHPGDL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102757423-B | Exo-and diastereoselective synthesis of himbacine analogs | SCHERING CORP. (US) | 2016-04-20 | — | — | CN | disclosed |
| EP-2399912-B1 | An exo-selective synthesis of himbacine analogs | MERCK SHARP & DOHME (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2196454-B1 | EXO-AND DIASTEREO-SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | MERCK SHARP & DOHME (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8618314-B2 | Exo- and diastereo-selective synthesis of himbacine analogs | MERCK SHARP & DOHME CORP. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-1846385-B1 | AN EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2196468-B1 | Exo-and diastereo-selective syntheses of himbacine analogs | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | THIRUVENGADAM TIRUVETTIPURAM K (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | THIRUVENGADAM TIRUVETTIPURAM K (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120296093-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | TOPROL ACQUISITION LLC | 2012-11-22 | — | — | US | disclosed |
| US-20120296093-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | TOPROL ACQUISITION LLC | 2012-11-22 | — | — | US | disclosed |
| WO-2008095646-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956023-A1 | Method for lithium exchange reactions | LONZA AG (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1848705-A2 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1846385-A2 | AN EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060247450-A1 | Exo- and diastereo- selective syntheses of himbacine analogs | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| US-20060217422-A1 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION | 2006-09-28 | — | — | US | disclosed |
| WO-2006076415-A2 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076452-A2 | AN EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-4154945-A | Fungicidal substituted imidazoles | THE BOOTS COMPANY LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4080462-A | Fungicidal compositions containing substituted imidazoles | THE BOOTS COMPANY LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247450-A1 | Exo- and diastereo- selective syntheses of himbacine analogs | EDNRA, EDNRB, NMBR | LMNA 2407/4885THRB 50/4885HPGD 1570/4885 |
| US-20060217422-A1 | Exo-selective synthesis of himbacine analogs | CHKB, BDKRB1, EDNRB | LMNA 3058/4885THRB 43/4885HPGD 3112/4885 |
| US-20120296093-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | EDNRA, EDNRB, NMBR | LMNA 2206/4885THRB 51/4885HPGD 1517/4885 |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | LMNA 3058/4885THRB 43/4885HPGD 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.